Vanguard Group
ORMP icon

Vanguard Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Vanguard Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-336,852
Closed -$2.92M – 4631
2022
Q1 		$2.92M Buy
336,852
+51,690
+18% +$530K ﹤0.01% 3790
2021
Q4 		$4.07M Buy
285,162
+125,467
+79% +$2.62M ﹤0.01% 3720
2021
Q3 		$3.51M Buy
159,695
+34,624
+28% +$590K ﹤0.01% 3846
2021
Q2 		$1.67M Buy
+125,071
New +$1.43M ﹤0.01% 4017

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's ORMP Position: Q2 2022 in Review

Vanguard Group sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 336,852 shares — an estimated $2.92M sold.

Vanguard Group first reported a position in ORMP in Q2 2021 and held it in 4 quarters. The position peaked at $4.07M in Q4 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Vanguard Group reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Vanguard Group sold 336,852 Oramed Pharmaceuticals shares in Q2 2022, an estimated $2.92M.
  • Vanguard Group first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Vanguard Group's Oramed Pharmaceuticals position peaked at $4.07M in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.